fulvestrant

Type: Keyphrase
Name: fulvestrant
First reported Apr 11 2014 - Updated Apr 11 2014 - 1 reports

Interview: AstraZeneca’s oncology expert Susan Galbraith on the company’s exciting pipeline

The full year report from Anglo-Swedish drug major AstraZeneca (LSE: AZN) in February was full of optimism. Chief executive Pascal Soriot stressed that 2013 had been a year of ‘momentum’ for the company and outlined three core therapy areas for 201, including ... [Published Pharma Letter - Apr 11 2014]
First reported Apr 08 2014 - Updated Apr 08 2014 - 1 reports

Encouraging Results from Pfizer's Palbociclib - Analyst Blog

Pfizer Inc. (NYSE: PFE) announced positive detailed results from the phase II PALOMA-1 study on its oncology candidate, palbociclib. The study evaluated post-menopausal women suffering from estrogen receptor positive (ER+), human epidermal growth factor ... [Published Benzinga.com - Apr 08 2014]
First reported Apr 07 2014 - Updated Apr 08 2014 - 4 reports

Encouraging Results from Pfizer's Palbociclib

Pfizer Inc. (PFE) announced positive detailed results from the phase II PALOMA-1 study on its oncology candidate, palbociclib. The study evaluated post-menopausal women suffering from estrogen receptor positive (ER+), human epidermal growth factor receptor ... [Published Yahoo! News - Apr 08 2014]
First reported Apr 06 2014 - Updated Apr 07 2014 - 2 reports

Pfizer’s novel CDK 4/6 inhibitor palbociclib plus letrozole significantly prolonged PFS in patients with advanced breast cancer

Pfizer Inc. announced detailed results from the PALOMA-1 study, a randomized phase 2 study of palbociclib (PD-0332991) in combination with letrozole. PALOMA-1 achieved its primary endpoint by significantly prolonging progression-free survival (PFS) compared ... [Published PharmaBiz - Apr 07 2014]
First reported Apr 06 2014 - Updated Apr 06 2014 - 1 reports

How I Treat Patients with HER2-Positive Metastatic Breast Cancer

SARA HURVITZ, MDImage ToolsIt is well recognized that the treatment of HER2-positive metastatic breast cancer has been revolutionized in the last 15 years—first by the introduction of trastuzumab; followed nine years later by lapatinib; and in the last ... [Published Oncology Times - Apr 06 2014]
Entities: Herceptin, T-DM1, Metastatic
First reported Apr 03 2014 - Updated Apr 03 2014 - 1 reports

MERRIMACK PHARMACEUTICALS : "Combination Therapies Comprising Anti-Erbb3 Agents" in Patent Application Approval Process

By a News Reporter-Staff News Editor at Women's Health Weekly -- A patent application by the inventors ZHANG, Bo ( Lynnfield, MA ); McDonagh, Charlotte ( Winchester, MA ); Huhalov, Alexandra ( Cambridge, MA ), filed on August 30, 2013 , was made available ... [Published 4 Traders - Apr 03 2014]
First reported Mar 28 2014 - Updated Mar 29 2014 - 2 reports

AstraZeneca Has a Promising Oncology Pipeline

March 28, 2014, 12:09:48 PMAstraZeneca’s Phase III pipeline is growing ahead of plan, chief executive  Pascal Soriot told a recent media briefing, and cancer drugs make up a major chunk of the pipeline.In oncology, olaparib for solid tumours, moxetumomab ... [Published American Journal of Managed Care - Mar 28 2014]
First reported Mar 13 2014 - Updated Mar 13 2014 - 1 reports

Oncology Stocks That Could Offer Supernormal Returns

A weighted portfolio of oncology investments can help an investor balance the high risk associated with the FDA approval process, and the high reward associated with early stage drugs and treatments. Here are three stocks that would fit into such a portfolio, ... [Published Investing.com - Mar 13 2014]
First reported Feb 13 2014 - Updated Feb 13 2014 - 1 reports

Fulvestrant 500 mg vs 250 mg in CONFIRM Trial

Related Biotechnology, Pharmaceutical and Healthcare NewsIn patients with locally advanced or metastatic estrogen receptor--positive breast cancer, which dosing improves the odds? Journal of the National Cancer InstituteOriginal Article: NEXT ARTICLE ... [Published BioPortfolio - Feb 13 2014]
First reported Dec 30 2013 - Updated Dec 30 2013 - 1 reports

Higher Dose of Faslodex Effective in Advanced Breast Cancer

Home » Syndicated Content » The final results are in—and they show that 500 mg of Faslodex® (fulvestrant) provides a significant advantage in overall survival compared to 250 mg of the drug in postmenopausal women with locally advanced or metastatic estrogen ... [Published BioPortfolio - Dec 30 2013]
First reported Nov 08 2013 - Updated Nov 08 2013 - 1 reports

2014 Pipeline Report: The Sprint to Value

Cancer: Multiple TargetsGenome-guided tumor diagnostics and treatments with the power to manipulate a patient's immune response have the potential to impact cancer outcomes in dramatic fashion. At the Cleveland Clinic's recent Medical Innovations Summit ... [Published Pharmaceutical Executive - Nov 08 2013]
First reported Oct 30 2013 - Updated Oct 30 2013 - 1 reports

Pfizer Pharmaceutical Selects Southern Cancer Center as First Site for International Clinical Trial

Breast cancer study promotes growth in local community oncology research. Pfizer Pharmaceutical has chosen Southern Cancer Center (SCC) as the first treatment center to participate in its PALOMA-3 clinical trial, which is an international study for women ... [Published PRWeb - Oct 30 2013]

Quotes

...Mace Rothenberg, senior vice president of Clinical Development and Medical Affairs and chief medical officer for Pfizer Oncology. "We are proud to be at the forefront of research and development with respect to this promising new class of investigational anticancer agents and have initiated a broad clinical development programme for palbociclib that includes breast and non-breast cancers.”"
...to inhibition of CDK-4/6," said Richard S Finn, M D , an associate professorprofessor of medicine at University of California Los Angeles (UCLA). "Further, a small lead-in phase I study conducted prior to this phase II trial showed that palbociclib and the antiestrogen drug letrozole could be given safely as a combination, with manageable side effects and also showed preliminary signs of good efficacy."
"FIG. 8 is a series of graphs showing MM-111 or lapatinib inhibition of ErbB3 (8a) or AKT (8b) activation in heregulin-stimulated cells incubated with inhibitor for 15 minutes, 1 hour, 4 hours, and 24 hours. FIG. 8c shows a comparison of IC50 for MM-111 and lapatinib at 1 hour and 24 hours for both BT474M3 cells and ZR75-30 cells."

More Content

All (21) | News (20) | Reports (0) | Blogs (0) | Audio/Video (0) | Fact Sheets (0) | Press Releases (1)
sort by: Date | Relevance
Interview: AstraZeneca’s oncology expert Susan ... [Published Pharma Letter - Apr 11 2014]
Encouraging Results from Pfizer's Palbociclib -... [Published Benzinga.com - Apr 08 2014]
Encouraging Results from Pfizer's Palbociclib [Published Yahoo! News - Apr 08 2014]
Encouraging Results from Pfizer's Palbociclib [Published Yahoo! Finance - Apr 08 2014]
Encouraging Results from Pfizer's Palbociclib [Published Zacks.com - Apr 08 2014]
ONLINE FIRST: CDK-4/6 Inhibitor Palbociclib Dou... [Published Oncology Times - Apr 07 2014]
Pfizer’s novel CDK 4/6 inhibitor palbociclib pl... [Published PharmaBiz - Apr 07 2014]
Palbociclib Shows Promising Results in Patients... [Published FierceBiotech - Apr 06 2014]
How I Treat Patients with HER2-Positive Metasta... [Published Oncology Times - Apr 06 2014]
MERRIMACK PHARMACEUTICALS : "Combination Therap... [Published 4 Traders - Apr 03 2014]
AstraZeneca Has a Promising Oncology Pipeline [Published American Journal of Managed Care - Mar 28 2014]
AstraZeneca ramps up oncology pipeline [Published Pharma Times - Mar 28 2014]
Oncology Stocks That Could Offer Supernormal Re... [Published Investing.com - Mar 13 2014]
Fulvestrant 500 mg vs 250 mg in CONFIRM Trial [Published BioPortfolio - Feb 13 2014]
MPI publishes data showing that MPI's product D... [Published GlobeNewswire: Advertising News - Feb 05 2014]
Higher Dose of Faslodex Effective in Advanced B... [Published BioPortfolio - Dec 30 2013]
2014 Pipeline Report: The Sprint to Value [Published Pharmaceutical Executive - Nov 08 2013]
Synta Announces Publication of First Patent App... [Published BioPortfolio - Oct 31 2013]
Pfizer Pharmaceutical Selects Southern Cancer C... [Published PRWeb - Oct 30 2013]
Estrogen receptors and methods of use [Published PharmCast - Oct 24 2013]
Lipid depot formulations [Published PharmCast - Oct 18 2013]
1
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Press Releases

sort by: Date | Relevance
MPI publishes data showing that MPI's product D... [Published GlobeNewswire: Advertising News - Feb 05 2014]
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.